S
ENTA icon

SignatureFD’s Enanta Pharmaceuticals ENTA Stock Holding History

SignatureFD’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-163
Closed -$2.85K – 3158
2024
Q1 		$2.85K Buy
+163
New +$2.16K ﹤0.01% 2702
2023
Q4 		– Sell
-978
Closed -$10.9K – 3170
2023
Q3 		$10.9K Buy
978
+748
+325% +$12K ﹤0.01% 2165
2023
Q2 		$4.92K Buy
230
+192
+505% +$5.66K ﹤0.01% 2522
2023
Q1 		$1.54K Sell
38
-60
-61% -$2.87K ﹤0.01% 2877
2022
Q4 		$4.56K Sell
98
-93
-49% -$4.24K ﹤0.01% 2515
2022
Q3 		$10K Buy
191
+25
+15% +$1.46K ﹤0.01% 2079
2022
Q2 		$8K Sell
166
-226
-58% -$12.3K ﹤0.01% 2221
2022
Q1 		$28K Buy
392
+182
+87% +$11.8K ﹤0.01% 1667
2021
Q4 		$16K Buy
210
+5
+2% +$392 ﹤0.01% 1875
2021
Q3 		$12K Sell
205
-14
-6% -$692 ﹤0.01% 1968
2021
Q2 		$10K Buy
219
+70
+47% +$3.43K ﹤0.01% 1977
2021
Q1 		$7K Buy
149
+41
+38% +$2.04K ﹤0.01% 2005
2020
Q4 		$5K Sell
108
-257
-70% -$11.3K ﹤0.01% 1946
2020
Q3 		$17K Buy
365
+190
+109% +$9.21K ﹤0.01% 1440
2020
Q2 		$9K Buy
175
+83
+90% +$4.29K ﹤0.01% 1599
2020
Q1 		$5K Buy
+92
New +$4.9K ﹤0.01% 1670

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SignatureFD's ENTA Position: Q2 2024 in Review

SignatureFD sold out of Enanta Pharmaceuticals (ENTA) in Q2 2024, closing a stake of 163 shares — an estimated $2.85K sold.

SignatureFD first reported a position in ENTA in Q1 2020 and held it in 16 quarters. The position peaked at $28K in Q1 2022. 100 funds tracked by Wall St. Rank hold ENTA as of Q2 2024.

  • SignatureFD reported no remaining Enanta Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • SignatureFD sold 163 Enanta Pharmaceuticals shares in Q2 2024, an estimated $2.85K.
  • SignatureFD first reported a position in Enanta Pharmaceuticals in Q1 2020 and held it in 16 quarters.
  • SignatureFD's Enanta Pharmaceuticals position peaked at $28K in Q1 2022.
  • 100 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2024.

Based on SignatureFD's 13F filing for Q2 2024, filed 29 Jul 2024.